The FDA has classified Vitruvias Therapeutics' recall of thyroid tablets as Class I due to potential superpotency, posing a risk of serious health issues. The affected lot includes approximately 3,655 units. 
The FDA has classified Vitruvias Therapeutics' recall of thyroid tablets as Class I due to potential superpotency, posing a risk of serious health issues. The affected lot includes approximately 3,655 units. 
<iframe src="https://hindustansphere.com/embed/cluster/8a9d28f1b279c466703a896b0b5eace3492d1e44" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA upgrades Vitruvias Therapeutics recall: Superpotent thyroid tablets could trigger heart problems; who is at risk?"></iframe>
The FDA has classified Vitruvias Therapeutics' recall of thyroid tablets as Class I due to potential superpotency, posing a risk of serious health issues. The affected lot includes approximately 3,655 units.&nbsp;
